AGTR1 and breast carcinoma: Moreover, losartan blocks breast tumor growth, invasion, angiogenesis and EMT prompted by AT1R overexpression [166,172], inhibits mammary tumor development and progression to invasive carcinoma [173] and potentiates the doxorubicin and paclitaxel-induced inhibitory effects on breast cancer growth and metastasis [174,175,176].